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Abstract
Background: Inactivation of tumor suppressor genes by promoter hypermethylation plays a key role in
the tumorgenesis. It is necessary to uncover the detailed pattern of whole genome-wide abnormal DNA
methylation during the development of gastric cancer (GC).
Method: We performed a genome-wide methylation detection using 12 paired of GC tissues and their
corresponding normal tissues. Methylation-specific PCR (MSP) and bisulphite sequencing (BSP) were used
to measure methylation status of specific CpG site. Based on the bioinformatic analysis, the cell phenotypes and
mouse model experiments were constructed to detect effect of the target gene. Using the Kaplan–Meier survival
curve, the clinical value of KCNMA1 was assessed in GC patients.
Results: The CpG site cg24113782 located at the promoter of KCNMA1 showed the most significant difference,
contributing to the commonly silenced KCNMA1in gastric cancer cells and primary GC tissues. The promoter
methylation of KCNMA1 was detected in 68.7% (77/112) of tumor tissues, compared with 16.2% (18/112)
of normal tissues (P < 0.001). The survival curve indicated that KCNMA1 hypermethylation was significantly
associated with the shortened survival in GC patients (P = 0.036). KCNMA1 significantly inhibited biological
malignant behavior of gastric cancer cell by inducing cell apoptosis in vitro, and suppressed xenograft tumor
growth in subcutaneous mouse models (both P < 0.001). Furthermore, the anti-tumor effect of KCNMA1was
mediated through suppressing the expression of PTK2.
Conclusion: KCNMA1 is a critical tumor suppressor in gastric carcinogenesis and its hypermethylation is an
independent prognostic factor in patients with gastric cancer.
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Background
Gastric cancer (GC) is one of the most common malig-
nancies and remains the second leading cause of cancer-
related death worldwide. Despite modified surgical and
adjuvant treatment strategy, the prognosis of GC
patients is poor, with a 5-year overall survival of less
than 25% [1, 2]. There are considerable evidences
indicating that epigenetic alterations, particularly
inactivation of tumor suppressor genes through pro-
moter hypermethylation, play an important role in the
development and progression of GC [3]. Identification of
such novel genes targeted by promoter hypermethylation
may provide insights into alternative approaches for
diagnostic and therapeutic targets and the epigenetic
mechanisms in GC. In normal cells, the pattern of DNA
methylation is handed down to the daughter cells during
mature cell division. However, the aberrant alterations in
the DNA methylation profile of mature cells are fre-
quently observed in many human cancers, including GC
[4, 5]. Therefore, identification of the differences of the
DNA methylation status in GC to reveal the role of
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epigenetic instability on the initiation and progression of
GC is necessary.
To uncover the genome-wide DNA methylation pro-
files of GC in a more comprehensive way, we performed
a microarray analysis between gastric cancer issues and
their matched normal tissues with Illumina Infinium
Human Methylation450 BeadChip array that include
>485,000 CpG sites distributed throughout the genome
[6]. We found that the gene, potassium channel, calcium
activated large conductance subfamily M alpha, member
1(KCNMA1), the function of which remains largely
unexplored, was moderated by promoter methylation in
gastric cancer. KCNMA1 (also named BK) potassium
channels are a diverse class of ion channels expressed in
many different cell types [7]. The protein encoded by
KCNMA1 represents the voltage and Ca2+-activated K+
channel, and is involved in the feedback inhibition of the
action potential frequency and Ca2+ influx [8, 9].
Emerging evidences have identified that the Ca2+ is
closely related to cell apoptosis [10, 11]. Moreover, by
bioinformatics analysis based on The Cancer Genome
Atlas (TCGA), we found the KCNMA1could regulate
the expression of FAK (focal adhesion kinase), also
named PTK2, which is a non-receptor tyrosine kinase
and moderate cancer proliferation, migration and sur-
vival [12]. And it may regulate the cell apoptosis by
PI3K-AKT pathway [13]. It is possible that the Ca2+ is
involved in apoptosis by cooperating with PTK2.
We reasoned the KCNMA1 contribute to the GC risk
by regulating the key apoptosis gene PTK2. In this study,
therefore, we set out to explore the expression profile,
epigenetic regulation, biological function, molecular
basis and clinical application of KCNMA1 in GC.
Methods
GC cell lines
A total of four GC cell lines (i.e., MGC-803, BGC-823,
SGC-7901, and MKN-28) and one normal human gastric
epithelial cell (GES-1) were used in this study. All cell
lines were maintained in RPMI-1640 medium (Gibco
BRL, Rockville, Maryland, USA) with 10% fetal bovine
serum (Gibco BRL). And the identity of the cell lines
were confirmed by short tandem repeat (STR).
Gastric tissue samples
Seventy-nine paired tumor and adjacent non-tumor
gastric samples were obtained from GC patients at the
Second Affiliated Hospital of Nanjing medical University
in Nanjing, China. A total of 75 patients with
histologically-confirmed gastric cancer and adjacent
non-tumor tissues were evaluated for KCNMA1 with
real-time PCR (RT-PCR) and 112 patients with
methylation-specific PCR (MSP). The 75 paired of GC
tissues were mainly collected from The Second Affiliated
Hospital of Nanjing Medical University, and 112 GC tis-
sues were from the First Affiliated Hospital of Nanjing
Medical University without paired adjacent tissues. All
subjects of this study signed informed consent for
obtaining the study specimens.
Genome-wide Methylation Profiling
DNA methylation analysis was performed by Shanghai
Genergy Co. Ltd (Shanghai, China) using the Illumina
Human Methylation450 BeadChip (Illumina). These ar-
rays contain probes for approximately 450,000 CpG loci
sites. Target was prepared and hybridized according to
the “Illumina Infinium HD Methylation Assay, Manual
Protocol”. The methylation level was computed as a β
value according to the normalized probe fluorescence
intensity ratios between methylated and unmethylated
signals: β value = signal intensity of the methylated allele
(sum of signal intensity of the unmethylated and methyl-
ated allele + 100). The DNA methylation level for each
interrogated CpG site was evaluated as a β value, which
ranged from 0 (not methylated) to 1 (fully methylated).
The significant P values of the normal tissue and tumor
tissue groups were calculated by paired Wilcox non
parametric test, and the Benjamini and Hochberg
method were used to carry out multiple test correction
calculation FDR [14]. We chose the maximum difference
of β value between the normal tissue and tumor tissue
groups in further research.
RNA extraction and Quantitative real-time PCR (qRT PCR)
The total RNA was extracted from tissues using Trizol
reagent (Invitrogen, CA, USA). The cDNA was synthe-
sized using M-MLV reverse transcriptase (Invitrogen)
after RNA extraction according to the manufacturer’s
instruction. The expression level of genes was detected
by qRT-PCR using SYBR Green assays (TaKaRa Biotech-
nology, Dalian, China). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was chose to act as an internal
control, and the assay was conducted by ABI 7900 sys-
tem (Applied Biosystems, CA, USA). To evaluate the
primer efficiency, we have used the standard curve to
calculate the amplification efficiency. The amplification
efficiency of GAPDH, KCNMA1 and PTK2 was 98.1,
96.3 and 97.5% respectively. The expression of each gene
was quantified according to fold change using 2−ΔΔCt
methods. The primers sequences are available in
Additional file 1: Table S1.
DNA extraction, MSP and BSP
The DNA of tissues was obtained using E.Z.N.A ™ tissue
DNA kit (Omega Bio-Tek. USA). Then the tissue DNA
was modified by EZ DNA Methylation-Gold™ Kit (Zymo
Research) according to the manufacturer’s instruction.
The MSP and BSP primer was designed by the Methyl
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Primer Express v1.0 (Applied Biosystems), as shown in
Additional file 1: Table S1.
Construction of KCNMA1 expression plasmid and RNA
interference
The full-length open reading frame sequence of
KCNMA1 was constructed by GenScript USA Inc.
(Nanjing, China) and then was subcloned into the mam-
malian expression vector pIRES-EGFP. The product was
verified by DNA sequencing. Three small interfering
RNA (siRNA) were synthesized to target PTK2 (RiboBio,
Guangzhou, China). After detection of the interference
efficiency, si-PTK2-2 (named si-PTK2 in this study) had
the optimal efficiency and was selected for the following
study. The sequences are shown in Additional file 1:
Table S1. GC cells, MGC-803 and BGC-823, were tran-
siently transfected with the KCNMA1 over-expression
plasmid and si-PTK2 using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA, USA) transfection reagent according
to the instruction. The pIRES-EGFP empty vector was
used as negative control (NC).
The malignant behaviors of cancer cells
Using GC cells, we performed a series of assays to detect
the effects of KCNMA1 on the malignant behaviors in-
cluding apoptosis assay, proliferation, colony formation
and migration. The detail of assay conditions was shown
in Additional file 2.
Subcutaneous xenograft models in vivo
MGC803 cells (1 × 107cells in 0.2 ml PBS) that was sta-
bly transfected with KCNMA1 expression vector or
empty vector were subcutaneously injected into the
dorsal right flank of 5-week-old male Balb/c nude mice
(n = 10 per group). The tumor diameter in the nude
mice was measured every 2 days for 2–3 weeks. After
20 days, all mice were sacrificed and the tumor weight
and size were measured. The experiment was approved
by the Animal Ethics Committee of Nanjing Medical
University.
Statistical analysis
The independent or paired t test was used to calculate
the difference between two preselected groups or paired
samples. The associations between the KCNMA1 methy-
lation and expression and clinic opathological character-
istics of GC patients were compared using Pearson’s χ2
test. The Kaplan Meier survival curves and log-rank test
were used to evaluate the relation between the overall
survival and methylation status. The P < 0.05 was
regarded as statistical significance.
Results
Identification of methylation status between gastric
cancer tissues and normal tissues
Twelve paired of the tumor and the paired normal tis-
sues were profiled (Additional file 1: Table S1). Results
of hierarchical clustering analysis on the most signifi-
cantly hypermethylation CpG site are shown in Fig. 1a.
This analysis revealed a remarkable segregation between
the tumor and the paired normal tissues. Through fur-
ther analysis, we found that the most of top 100 hyper-
methylation site locate the promoter of the genes
(Fig. 1b). And the top 10 high methylated CpG sites can
well distinguish the tumor tissues from the normal tis-
sues (Fig. 1c). Interesting, the CpG site cg24113782 with
most significant difference was located in the promoter
region of KCNMA1. Moreover, this result was also sup-
ported by the data from the independent TCGA data.
The above results indicated cg24113782 had a notably
high β-score value in the cancer tissues compared nor-
mal tissues (P < 0.001) (Additional file 3: Figure S1). In
addition, this finding was also identified in the Human
Methylation 27 array from TCGA, which has a low
density and mainly focuses on CpG-sites mapping to
gene promoter regions. Although the cg24113782 site
was not included in the HumanMethylation 27 array, we
found the other CpG site cg04688368 in the Human-
Methylation27 array which also located on the KCNMA1
promoter region. The β-score value of cg04688368
between tumor and paired normal tissues had a signifi-
cant difference in the paired GC tissue (P < 0.001,
Additional file 3: Figure S1).
Silence or downregulation of KCNMA1 by promoter
methylation in gastric cancer cells and tissues
The expression of KCNMA1 was detected in the GC
cells (i.e., MGC-803, BGC-823, MKN-82, SGC-7901)
and the normal human gastric epithelial cell line (GES1)
using RT-PCR (Additional file 3: Figure S2). The mRNA
expression of KCNMA1 was silenced or reduced in the
GC cells compared with normal human gastric epithelial
cell. To identify whether the cancer cell methylation
directly mediates KCNMA1 expression, we treated the
two cell lines (i.e., MGC-803 and BGC-823) with the
demethylation agent, 5-Aza-2′-deoxycytidine (5-Aza;
Sigma-Aldrich), for 72 h. Notably, this treatment re-
stored expression of KCNMA1 in the two silenced cell
lines (Additional file 3: Figure S2), suggesting that the
expression silence of KCNMA1 was moderated by the
aberrant promoter methylation.
To detect the contribution of promoter methylation to
the down-regulation of KCNMA1 for tumor and paired
normal tissues, methylation status of its promoter was
examined by methylation-specific PCR (MSP) in 112
paired tissues. We found 68.7% (77/112) GC tissues were
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methylated, but only 16.2% (18/112) normal tissues were
methylated (Fig. 2a), and the BSP results also confirmed
this finding (Fig. 2b). In addition, we detected the
expression of KCNMA1 in 75 paired of cancer and
normal tissues. The expression level of KCNMA1 in
cancer tissues was significantly decreased compared
with normal tissues (P = 0.008, Fig. 2c, d). The same
result was found in TCGA and GEO data (Additional
file 3: Figure S1). As shown in Table 1, the aberrant
KCNMA1 methylation status in GC tissues was asso-
ciated with tumor sizes and depth of invasion. Mean-
while, we found the aberrant expression contributed
to the tumor sizes in Table 2.
KCNMA1 is an independent predictor of prognosis in
patients with GC
The association between KCNMA1 methylation status
and clinical outcome was analyzed in 91 patients with
GC with known survival data. As shown in Fig. 2e, GC
patients with KCNMA1 methylation had significantly
shorter survival than others (P = 0.038, log-rank test).
Ectopic expression of KCNMA1 suppressed GC cell
proliferation, migration, invasion and colony formation
Considering frequent silencing of KCNMA1 in primary
cancers and GC cell lines but not in normal gastric tis-
sues, it suggested that KCNMA1 may act as probably a
tumor suppressor. KCNMA1-expressing plasmid was
stably transfected into MGC803 and BGC823 cells. Re-
expression of KCNMA1 was confirmed by RT-PCR and
Western blot analysis (Fig. 3a). Firstly, CCK-8 assay
showed that proliferation of MGC803 and BGC823
cells were remarkably suppressed after KCNMA1over-
expression for 24 h, 48 h and 72 h compared with
those transfected with NC vectors (Fig. 3b). Com-
pared with MGC803 and BGC823 cells transfected
with NC vector, the cells with over-expression of
KCNMA1 for 48 h showed significantly decreased
migration ability (P < 0.01, Fig. 3c). Besides, the sup-
pression effect on invasion was also observed in both
the two cells after 48 h of transfection (P < 0.01,
Fig. 3d). Moreover, the inhibitory effect on GC cell
growth was further confirmed by colony formation
assay. The colonies formed by KCNMA1-transfected
Fig. 1 Hierarchical clustering analysis of the microarray assay. a The heat map of the different methylated site between the gastric carcinoma
and paired corresponding normal tissues. b The gene location of the most 100 significantly hypermethylated CpG sites. c Hierarchical clustering
analysis on the most 10 significantly hypermethylated and hypomethylationCpG sites. N, normal tissues, T, gastric carcinoma tissues. TSS1500,
1500 bases before the transcription start site. TSS200, 200 bases before the transcription start site. Body, the intron and exon of gene
Ma et al. Molecular Cancer  (2017) 16:46 Page 4 of 10
cells were significantly smaller and fewer than those
formed by NC vector-transfected cells (P < 0.01,
Fig. 3e).
KCNMA1 induced cell apoptosis
Suppression of tumor cell growth is usually involved in
concomitant activation of cell apoptosis pathways.
Therefore we detected the contribution of apoptosis to
the growth inhibition of KCNMA1over-expression cells
using flow cytometry (Fig. 4f ). The results indicated
an increase in the numbers of both early apoptotic cells
(P < 0.01) and late apoptotic cells (P < 0.01) in KCNMA1-
transfected MGC803 and BGC823 cells compared with
those transfected with NC vector (Fig. 4f).
Identification of genes modulated by KCNMA1 in GC cell
lines
To gain insights into the molecular basis of apoptosis
KCNMA1-modulated, the downstream target genes were
characterized through cBioPortal for Cancer Genomics
(Additional file 3: Figure S3) and found that the PTK2
gene involved in FAK apoptosis pathways may be corre-
lated with KCNMA1. Firstly, we found that the PTK2
was significantly high expression in tumor tissues than
paired normal tissues (Fig. 4a). Then, the correlation
between the KCNMA1 and PTK2 was examined in gas-
tric cancer tissues, and the result indicated that the ex-
pression levels of KCNMA1 and PTK2 were significantly
correlated in a negative direction (r = −0.364, P < 0.01,
Fig. 2 The difference of KCNMA1 methylation and expression between the gastric carcinoma and paired corresponding non-cancerous tissues,
and the prognosis value. a Analysis of promoter methylation of KCNMA1 in gastric tumor tissues and paired corresponding normal tissues. The
presence of PCR products in lane M indicates the presence of methylated alleles, and in lane U indicates the presence of unmethylated alleles.
N = non-tumor, T = tumor; b BGS analysis also confirmed high levels of promoter methylation in a paired carcinoma tissues and corresponding
normal tissues; Level of KCNMA1 mRNA (c) and protein (d) in the carcinoma and adjacent tissue; e The influence of KCNMA1 methylation on GC
patients prognosis. N, normal tissues, T, gastric carcinoma
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Fig. 4b), which was further confirmed by the GEO data (r
= −0.25, P = 0.036, Fig. 4b) (GSE29272). Taking into con-
sideration the published researches, the function of antitu-
mor of PTK2 was also found in this study (Fig. 4e, f, g and
Additional file 3: Figure S5). When KCNMA1-expressing
plasmid was transfected into MGC803 and BGC823 cells,
the expression level of PTK2 was detected by RT-PCR and
western blotting. As shown in Fig. 4d, the expression of
PTK2 had a significant decrease compared with NC cells.
Knockdown of PTK2 expression by siRNA
In order to identify whether the observed antitumor
effects of KCNMA1 was the consequence of its down-
regulation of PTK2 gene, knockdown of PTK2 expres-
sion was achieved by siRNA interference. RT-PCR
results of the interfered cells indicated that PTK2
expression was remarkable decrease, except for si-PTK2-1
(Additional file 3: Figure S4). In the further study, si-PTK2
with the highest inhibition ratio up to 75% was selected.
Malignant phenotypes of MGC803 and BGC823 cells
were monitored repeatedly with both KCNMA1 over-
expressing and PTK2 knockdown.
Repeating observation on cell phenotype after KCNMA1-
expressing plasmid and si-PTK2 transfected
In the repeated CCK-8 assay, we found that suppressed role
of KCNMA1on GC cells proliferation was markedly weak-
ened with co-transfection of KCNMA1 vector and si-PTK2.
As the presented in Fig. 4e, there was no significant differ-
ence in proliferation ratio of treated BGC823 and
MGC803cells in the co-transfection of KCNMA1 vector and
si-PTK2 groups, compared with only the si-PTK2 groups.
Similarly, inhibitory ability on gastric cancer cell migration
and invasion was also attenuated by si-PTK2, that is,
KCNMA1 did not have the ability to suppress migration and
invasion of gastric cancer cells after PTK2 was knockdown
Table 1 Clinicopathological features of KCNMA1 promoter






Age (mean ± SD) 64.44 ± 1.00 61.81 ± 1.86 0.182
Gender
Male 50 22 0.879
Female 27 13
Tumor sizes
≤ 5 cm 35 26 0.005
> 5 cm 42 9
Depth of invasion
T1+ T2 17 2 0.032
T3+ T4 60 33
Lymphnode metastasis





M0 67 29 0.560
M1 10 6
TNM stages




The entries in bold showed the P value is less than 0.05
Table 2 The relationship between KCNMA1 expression and





KCNMA1 expression P value
High Low
Age(years)
< 60 27 13 14 0.878
≥ 60 48 24 24
Sex
Male 62 30 32 0.720
Female 13 7 6
Tumor size
≤ 5 cm 42 26 16 0.014
> 5 cm 33 11 22
Tumor site
Cardia 26 12 14 0.922
Non-cardia 47 24 23
Histological type
Diffuse 41 21 20 0.721
Intestinal 34 16 18
Depth of invasion
T1 + T2 15 4 11 0.179
T3 + T4 60 20 35
Lymph nodedistant metastasis
N0 + N1 20 11 9 0.554
N2 + N3 55 26 29
Distant metastasis
M0 62 30 32 0.720
M1 13 7 6
TNM
I + II 22 10 12 0.665
III + IV 53 27 26
The entries in bold showed the P value is less than 0.05
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(Fig. 4f). Furthermore, the differences were not found
on inhibiting the cell colony formation between
KCNMA1 vector and si-PTK2 co-transfected cells and
cells with transfection of si-PTK2 groups (Fig. 4g).
KCNMA1 repressed the growth of subcutaneous xenograft
tumours in nude mice
The subcutaneous xenograft tumor models were used to
explore the effect of KCNMA1 on gastric tumor cell growth
in vivo. The empty vector transfected and subcutaneously
injecting KCNMA1-transfected MGC803 cells were inocu-
lated in nude mice. Then the status of subcutaneous tumor
growth was recorded and monitored in the two groups. As
shown in Fig. 5a, b and d, KCNMA1can significantly atten-
uates the growth of tumor volume and tumor volumes
were compared with control cells (P < 0.001). And com-
pared with NC cells at termination of the experiment, the
weight of tumors with KCNMA1-transfected cells was also
significantly reduced (P < 0.001, Fig. 5c).
Discussion
In the present study, we have identified that KCNMA1 is
commonly silenced or down-regulated in primary gastric
cancer tissues and gastric cancer cell lines due to pro-
moter hypermethylation. In addition, the publicly avail-
able GEO and TCGA datasets were used to confirm that
finding. The expression of KCNMA1can be reactivated
by pharmacological demethylation, which inferred that
promoter methylation is the primary mechanism for the
silencing of KCNMA1 in GC.
The clinical outcome of GC generally depends on the
aggressiveness of individual tumors and growth status.
TNM stage is still the critical clinical factor that influ-
ences the prognosis of cancer patient. However, recur-
rence of many GC patients often occurs at early stages.
Identifying additional prognostic makers, which can
provide better risk assessment to extend survival, is
necessary and crucial. We explored the clinical import-
ance of KCNMA1 methylation in 91 patients with GC,
and found KCNMA1methylation was an independent
predictive biomarker of unfavorable outcome in patients
with GC by multivariate Cox regression analysis. Many
studies have indicated the promoter methylation can
serve as a promising prognostic biomarker in gastric
cancers [5, 15–17]. Our findings show that KCNMA1
hypermethylation may act as a new valuable marker for
Fig. 3 In vitro gain-function assays on KCNMA1. a Ectopic expression of KCNMA1 in BGC803 and MGC823 cells at mRNA and protein levels was
confirmed by RT-PCR and western blot analysis. b KCNMA1 significantly inhibited cell viability. c Representative images of invasion assays for
BGC803 and MGC823 cells transfected with control and KCNMA1 vector, error bars, s.d. n = 3 technical replicates. d Representative images of a
migration assay for BGC803 and MGC823 cells transfected with control and KCNMA1 vector, error bars, s.d. n = 3 technical replicates. e KCNMA1
significantly inhibited cell colony formation ability. f KCNMA1 induces the apoptosis of BGC803 and MGC-823. (F_left) The cells were cultured for
48 h, the level of apoptosis was determined by flow cytometry, representative data from one of the three experiments was shown. (F_right) After
MGC-823 transfected with KCNMA1, UR percentage + LR percentage in NC are less than cell treat with KCNMA1.*P < 0.01
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Fig. 4 The association between KCNMA1 and PTK2, and Repeating observation on malignant cell behavior after co-transfected with NC, KCNMA1
vector and si-PTK2. a The expression of PTK2 in gastric carcinoma and paired corresponding normal tissues. b Expression levels of KCNMA1
and PTK2 in tissues were significantly correlated in a negative direction. c The correlation of KCNMA1 and PTK2 was verified in GEO (GSE29272).
d The KCNMA1 suppress the expression of PTK2, and the relation were identified in BGC803 and MGC823 cells at mRNA and protein levels was
confirmed by RT-PCR and western blot analysis. Inhibitory role of KCNMA1 on malignant cell phenotype, i.e. e invasion and migration; f proliferation
and (g) colony formation; was diminished after PTK2 was knockdown.*P < 0.01, ** P < 0.001
Fig. 5 KCNMA1 suppresses gastric cancer cell growth in xenograft mice. a Representative burdened nude mice in KCNMA1 re-expressed and NC
in MGC803 cells. Red arrows show position of subcutaneous tumors. b Representative xenografts in KCNMA1 re-expressed and NC in MGC803
cells. c Tumor weight in nude mice at the 18 day after inoculation of KCNMA1 NC and re-expressed MGC803 cells. Bars: mean of 7 mice.
d The tumor volumes for KCNMA1 NC and re-expressed MGC803 cell xenografts. Points: mean of 7 mice. **P < 0.001
Ma et al. Molecular Cancer  (2017) 16:46 Page 8 of 10
predicting the prognosis of patients with GC. KCNMA1
was uncovered to be commonly downregulated in patients
with GC, which implied the key role of the functional si-
lence of KCNMA1 because of promoter methylation dur-
ing carcinogenesis. In this study, we have not found the
difference of methylated KCNMA1 between intestinal and
diffuse tumor types, which meant the KCNMA1 may be
not involved in the lauren classification.
We further investigated the putative tumor suppressor
function of KCNMA1 in human gastric cancer both in
vitro and in vivo assays. Compared with empty vector
transfection, ectopic expression of KCNMA1 in the
down-regulated MGC803 and BGC823 cells significantly
suppressed cell viability and reduced colony formation
ability. Moreover, MGC803 and BGC823 cells of over-
expressing KCNMA1 showed significantly decreased
ability in invasion and migration and suppressed the
growth of subcutaneous xenograft tumors in nude mice.
The mechanism by which KCNMA1 suppressed malig-
nant behaviors of the gastric cancer cell was mediated
by inducing cell apoptosis. The apoptosis by KCNMA1
was associated with the focal adhesion kinase (FAK), also
named PTK2, which is a cytoplasmic protein tyrosine
kinase. PTK2 can enhance tumor progression and me-
tastasis through effects on cancer cells, as well as stro-
mal cells of the tumor microenvironment [18–20]. The
kinase-dependent and kinase-independent functions of
PTK2 moderate cell movement, invasion, survival and
cancer stem cell self-renewal [21]. We found the
KCNMA1 down-regulated the expression of PTK2, and
promoted the apoptosis of GC cell lines.
The role of PTK2 as a major player in suppressing the
apoptosis of cancer cell has been well revealed, and
PTK2 is often expressed at aberrant high levels in cancer
cells [22–24]. Studies have identified its downstream tar-
get PI3K-AKT pathway was involved in the functions of
various kinds of cells including apoptosis [13, 25, 26].
Moreover, emerging studies have confirmed the inter-
action between the KCNMA1 and PI3K [27]. Our
research revealed the molecular mechanism that the
KCNMA1 can moderate the PTK2. This present study
showed the significantly reduced cell proliferation, inva-
sion and metastasis by KCNMA1 were related to induc-
tion of apoptosis, in which the PTK2 play a crucial role.
We proposed that aberrant KCNMA1 expression can dis-
turb the K+ channel function, and thus activate the FAK
pathway, which play a key role on the cell apoptosis [21].
However, it needed further functional studies to identify.
Some studies have explored the mechanism of
KCNMA1 in the tumorigenesis. KCNMA1 protein
(also named BK) was the pore-forming α subunit of
the α-subunit of the large conductance, voltage and
Ca2+-activated K+ channel, and was thought to play
several roles in cancer biology [28–31]. BK channels can
promote growth and spreading of breast, prostate and gli-
omas tumor [32–35]. Some studies found that BK chan-
nels do not participate in glioma cell division [36] and
genetic knock-down of BKα assist osteosarcoma develop-
ment [37]. So the role of BK channel in human tumor
may play a very complex one. In the above study, the
researchers identified the KCNMA1 generally acted as
oncogene. However, in this study we found the KCNMA1
was down-regulated in the tumor tissues due to the
methylation of promoter and played a tumor suppressor
role. This finding uncovered the possible new mechanism
that KCNMA1 was involved in carcinogenesis.
Conclusion
In conclusion, we have identified a novel tumor suppressive
gene, KCNMA1, which is frequently inactivated in gastric
cancer because of promoter methylation. KCNMA1 exerts
a tumor suppressive function by regulating the PTK2 ex-
pression to activate the PI3K-AKT pathway. In addition,
promoter hypermethylation of KCNMA1may serve as a po-
tential prognostic biomarker in patients with gastric cancer.
Additional files
Additional file 1: Table S1. Clinical characteristics of 12 gastric cancer
cases selected in microarray analysis. Table S2. Sequences of primers
used in RT-PCR and MSP assay. (PDF 113 kb)
Additional file 2: Supplementary materials. (PDF 82 kb)
Additional file 3: Supplementary figure. (PDF 387 kb)
Abbreviations
BSP: Bisulphite sequencing; FAK: Focal adhesion kinase; GC: Gastric cancer;
KCNMA1: Potassium channel, calcium activated large conductance subfamily
M alpha, member 1; MSP: Methylation-specific PCR
Acknowledgments
This study was partly supported by National Natural Science Foundation
of China (81473049, 81230068, and 81302490), Jiangsu Provincial Science
and Technology Innovation Team, Jiangsu Provincial Postdoctoral Science
Foundation funded project (1501081C), China Postdoctoral Science
Foundation funded project (2015 M580449), Collaborative Innovation Center
For Cancer Personalized Medicine, and the Priority Academic Program
Development of Jiangsu Higher Education Institutions (Public Health and
Preventive Medicine).
Availability of data and materials
Yes
Authors’ contributions
ZZ, WM, GW, MG, LH, and HQ designed and performed the research. LY, CH,
ZQ, QF, and TG collected data. DM, MG, and GY analyzed and interpreted
data. DM and GY performed statistical analysis. MG, LH, and HQ wrote the
draft manuscript. All authors contributed to the writing and reviewing of the
manuscript, and approved the final manuscript for submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Yes
Ma et al. Molecular Cancer  (2017) 16:46 Page 9 of 10
Ethics approval and consent to participate
The research was approved by the Ethics Committee of Nanjing Medical
University.
Author details
1Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer
Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical
University, Nanjing, China. 2Department of Genetic Toxicology, The Key
Laboratory of Modern Toxicology of Ministry of Education, School of Public
Health, Nanjing Medical University, Nanjing, China. 3Department of General
Surgery, Yixing Tumor Hospital, Yixing, China. 4Department of General
Surgery, The Second Affiliated Hospital of Nanjing Medical University,
Nanjing, China. 5Core Laboratory, Nantong Tumor Hospital, Nantong, China.
6Department of General Surgery, Huai-An First People’s Hospital Affiliated to
Nanjing Medical University, Huai-An, China. 7Department of Environmental
Genomics, School of Public Health, Nanjing Medical University, 101
Longmian AvenueJiangning District, Nanjing 211166, China.
Received: 23 July 2016 Accepted: 5 February 2017
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
2. Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J,
Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, et al. Improved survival of
gastric cancer with tumour Epstein-Barr virus positivity: an international
pooled analysis. Gut. 2014;63:236–43.
3. Choi IS, Wu TT. Epigenetic alterations in gastric carcinogenesis. Cell Res.
2005;15:247–54.
4. Wang K, Liang Q, Li X, Tsoi H, Zhang J, Wang H, Go MY, Chiu PW, Ng EK,
Sung JJ, Yu J. MDGA2 is a novel tumour suppressor cooperating with
DMAP1 in gastric cancer and is associated with disease outcome. Gut. 2016;
65:1619–31.
5. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP,
Tong JH, Ying JM, et al. Methylation of protocadherin 10, a novel tumor
suppressor, is associated with poor prognosis in patients with gastric
cancer. Gastroenterology. 2009;136:640–51. e641.
6. Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerstrom-Billai F,
Jagodic M, Sundberg CJ, Ekstrom TJ, Teschendorff AE, Tegner J, Gomez-
Cabrero D. An evaluation of analysis pipelines for DNA methylation profiling
using the Illumina HumanMethylation450 BeadChip platform. Epigenetics.
2013;8:333–46.
7. Ouadid-Ahidouch H, Ahidouch A. K+ channel expression in human breast
cancer cells: involvement in cell cycle regulation and carcinogenesis.
J Membr Biol. 2008;221:1–6.
8. Marrion NV, Tavalin SJ. Selective activation of Ca2 + -activated K+ channels by
co-localized Ca2+ channels in hippocampal neurons. Nature. 1998;395:900–5.
9. Sah P, Faber ES. Channels underlying neuronal calcium-activated potassium
currents. Prog Neurobiol. 2002;66:345–53.
10. Mizuno N, Yoshitomi H, Ishida H, Kuromi H, Kawaki J, Seino Y, Seino S.
Altered bcl-2 and bax expression and intracellular Ca2+ signaling in
apoptosis of pancreatic cells and the impairment of glucose-induced insulin
secretion. Endocrinology. 1998;139:1429–39.
11. Li W, Ouyang Z, Zhang Q, Wang L, Shen Y, Wu X, Gu Y, Shu Y, Yu B, Sun Y,
Xu Q. SBF-1 exerts strong anticervical cancer effect through inducing
endoplasmic reticulum stress-associated cell death via targeting sarco/
endoplasmic reticulum Ca(2+)-ATPase 2. Cell Death Dis. 2014;5:e1581.
12. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and
cancer cells. Curr Opin Cell Biol. 2006;18:516–23.
13. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer.
Cancer Metastasis Rev. 2009;28:35–49.
14. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery
rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.
15. Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q, Jin H, Zeng Z, Sung JJ, Yu J.
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for
gastric cancer, is associated with poor survival. Gut. 2012;61:977–85.
16. Wang S, Cheng Y, Du W, Lu L, Zhou L, Wang H, Kang W, Li X, Tao Q, Sung
JJ, Yu J. Zinc-finger protein 545 is a novel tumour suppressor that acts
by inhibiting ribosomal RNA transcription in gastric cancer. Gut. 2013;
62:833–41.
17. Tomita H, Takaishi S, Menheniott TR, Yang X, Shibata W, Jin G, Betz KS,
Kawakami K, Minamoto T, Tomasetto C, et al. Inhibition of gastric
carcinogenesis by the hormone gastrin is mediated by suppression of
TFF1 epigenetic silencing. Gastroenterology. 2011;140:879–91.
18. McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F,
Hodivala-Dilke K, Metzger D, Chambon P, Grant SG, Frame MC. Specific
deletion of focal adhesion kinase suppresses tumor formation and blocks
malignant progression. Genes Dev. 2004;18:2998–3003.
19. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling
directs the proliferation of metastatic cancer cells disseminated in the lungs.
Proc Natl Acad Sci U S A. 2009;106:10290–5.
20. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I,
Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for
tumour angiogenesis. EMBO Mol Med. 2010;2:516–28.
21. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings
and clinical applications. Nat Rev Cancer. 2014;14:598–610.
22. Jean C, Chen XL, Nam JO, Tancioni I, Uryu S, Lawson C, Ward KK, Walsh CT,
Miller NL, Ghassemian M, et al. Inhibition of endothelial FAK activity prevents
tumor metastasis by enhancing barrier function. J Cell Biol. 2014;204:247–63.
23. Cabrita MA, Jones LM, Quizi JL, Sabourin LA, McKay BC, Addison CL. Focal
adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol.
2011;5:517–26.
24. Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y,
Behrens C, Dellinger MT, Brekken RA, Wistuba II, et al. RHOA-FAK is a
required signaling axis for the maintenance of KRAS-driven lung
adenocarcinomas. Cancer Discov. 2013;3:444–57.
25. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG.
Ras- and PI3K-dependent breast tumorigenesis in mice and humans
requires focal adhesion kinase signaling. J Clin Invest. 2009;119:252–66.
26. Chen JS, Huang XH, Wang Q, Huang JQ, Zhang LJ, Chen XL, Lei J, Cheng
ZX. Sonic hedgehog signaling pathway induces cell migration and invasion
through focal adhesion kinase/AKT signaling-mediated activation of matrix
metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis. 2013;
34:10–9.
27. Vaithianathan T, Bukiya A, Liu J, Liu P, Asuncion-Chin M, Fan Z, Dopico A.
Direct regulation of BK channels by phosphatidylinositol 4,5-bisphosphate
as a novel signaling pathway. J Gen Physiol. 2008;132:13–28.
28. Lang F, Foller M, Lang KS, Lang PA, Ritter M, Gulbins E, Vereninov A, Huber
SM. Ion channels in cell proliferation and apoptotic cell death. J Membr Biol.
2005;205:147–57.
29. MacFarlane SN, Sontheimer H. Changes in ion channel expression accompany
cell cycle progression of spinal cord astrocytes. Glia. 2000;30:39–48.
30. Weaver AK, Liu X, Sontheimer H. Role for calcium-activated potassium
channels (BK) in growth control of human malignant glioma cells.
J Neurosci Res. 2004;78:224–34.
31. Pancrazio JJ, Tabbara IA, Kim YI. Voltage-activated K+ conductance and cell
proliferation in small-cell lung cancer. Anticancer Res. 1993;13:1231–4.
32. Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, Mihatsch MJ,
Kunzelmann K, Bubendorf L. KCNMA1 gene amplification promotes tumor
cell proliferation in human prostate cancer. Oncogene. 2007;26:2525–34.
33. Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, Couraud PO,
Ningaraj NS. Role of KCNMA1 gene in breast cancer invasion and metastasis
to brain. BMC Cancer. 2009;9:258.
34. Bury M, Girault A, Megalizzi V, Spiegl-Kreinecker S, Mathieu V, Berger W,
Evidente A, Kornienko A, Gailly P, Vandier C, Kiss R. Ophiobolin A induces
paraptosis-like cell death in human glioblastoma cells by decreasing BKCa
channel activity. Cell Death Dis. 2013;4:e561.
35. Basrai D, Kraft R, Bollensdorff C, Liebmann L, Benndorf K, Patt S. BK channel
blockers inhibit potassium-induced proliferation of human astrocytoma
cells. Neuroreport. 2002;13:403–7.
36. Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH. Calcium-activated
potassium channels BK and IK1 are functionally expressed in human
gliomas but do not regulate cell proliferation. PLoS One. 2010;5:e12304.
37. Cambien B, Rezzonico R, Vitale S, Rouzaire-Dubois B, Dubois JM, Barthel R,
Karimdjee BS, Mograbi B, Schmid-Alliana A, Schmid-Antomarchi H. Silencing
of hSlo potassium channels in human osteosarcoma cells promotes
tumorigenesis. Int J Cancer. 2008;123:365–71.
Ma et al. Molecular Cancer  (2017) 16:46 Page 10 of 10
